NCT06212102

Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation

Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation: A Randomized Controlled Non-inferiority Trial

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Bedaya Hospital · Academic / Other
• Sex: Female
• Age: 35 Years – 44 Years
• Healthy volunteers: Not accepted

Summary

The aim of this randomized controlled trial was to compare the efficacy and cost-effectiveness of using progestin with GnRH antagonist to prevent premature LH surge in poor responders undergoing double stimulation protocol.

Conditions

• Infertility

Interventions

Type	Name	Description
DRUG	Progestin primed ovarian stimulation	HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.
DRUG	GnRH antagonist	HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.

Timeline

• Start date: 2024-02-01
• Primary completion: 2026-03-01
• Completion: 2026-12-01
• First posted: 2024-01-18
• Last updated: 2024-01-23

Locations

1 site across 1 country: Egypt